KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Liabilities and Shareholders Equity: 2018-2025

Historic Liabilities and Shareholders Equity for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to $641.9 million.

  • Twist Bioscience's Liabilities and Shareholders Equity rose 4.48% to $641.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 7.38%. This contributed to the annual value of $641.9 million for FY2025, which is 4.48% up from last year.
  • Latest data reveals that Twist Bioscience reported Liabilities and Shareholders Equity of $641.9 million as of FY2025, which was up 4.48% from $614.3 million recorded in FY2024.
  • Twist Bioscience's 5-year Liabilities and Shareholders Equity high stood at $961.4 million for FY2022, and its period low was $614.3 million during FY2024.
  • In the last 3 years, Twist Bioscience's Liabilities and Shareholders Equity had a median value of $641.9 million in 2025 and averaged $677.5 million.
  • Per our database at Business Quant, Twist Bioscience's Liabilities and Shareholders Equity spiked by 76.02% in 2021 and then dropped by 20.88% in 2024.
  • Over the past 5 years, Twist Bioscience's Liabilities and Shareholders Equity (Yearly) stood at $702.1 million in 2021, then surged by 36.93% to $961.4 million in 2022, then dropped by 19.24% to $776.4 million in 2023, then declined by 20.88% to $614.3 million in 2024, then grew by 4.48% to $641.9 million in 2025.